Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | ASPEN: zanubrutinib vs ibrutinib in Waldenström’s macroglobulinemia

Meletios Dimopoulos • 3 Jun 2020
EHA 2020
Rare Diseases Waldenström’s Macroglobulinemia Ibrutinib Zanubrutinib
ASPEN

Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, reports results from the Phase III ASPEN trial (NCT03053440) which investigated zanubrutinib versus ibrutinib in Waldenström’s macroglobulinemia. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Meletios Dimopoulos

Sustained MRD negativity and long-term outcomes in DREAMM-8
1:09
Sustained MRD negativity and long-term outcomes in DREAMM-8
Meletios Dimopoulos • 23 Sep 2026
Mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in relapsed myeloma
1:20
Mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) in relapsed myeloma
Meletios Dimopoulos • 23 Sep 2026
IsaVCd and IsaR maintenance in newly diagnosed myeloma with severe renal impairment
1:40
IsaVCd and IsaR maintenance in newly diagnosed myeloma with severe renal impairment
Meletios Dimopoulos • 23 Sep 2026
Individualizing CAR-T and bispecific antibody sequencing in multiple myeloma
0:59
Individualizing CAR-T and bispecific antibody sequencing in multiple myeloma
Meletios Dimopoulos • 10 Sep 2026

Related Videos

BPDCN: unmet needs, CD123-targeted therapies and novel targets
15:50
BPDCN: unmet needs, CD123-targeted therapies and novel targets
Naveen Pemmaraju • 19 Sep 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
2:19
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
1:39
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
Elena Zamagni • 25 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals